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Introduction 
As COVID-19 wreaks havoc across the globe, the UK has been particularly hard hit. 
The current death toll [up to 1st May 2020] stands at 36 110 across Great Britain, of 
which 20 373 are male and 15 737 are female [see Figure 1]. This disparity in male 
mortality has been noted elsewhere,[1–4] and was also recognised during the two 
previous significant outbreaks of coronavirus: the 2003 Severe Acute Respiratory 
Syndrome [SARS-CoV] [5,6] and the 2012 Middle East Respiratory Syndrome 
[MERS]. [7] In particular, during the SARS-CoV outbreak men had a higher case 
fatality rate of 21.9% as compared to 13.2% for females, and twice as many male-to-
female deaths in the 0–44 year age range.[5]  
It is too soon for certainty as to why men are more at risk, but our knowledge of the 
biological, behavioural and socio-cultural factors involved is growing and the picture 
is getting clearer. This paper will focus onto what is currently understood about the 
biological implications of being male on the course of the disease. 
Picture COVID-19 binding to an angiotensin converting enzyme 2 (ACE2) 
receptor 
 
As well as gender, age is seen to be one of the most important risk factors for 
developing severe disease and a higher mortality,[8] with the median age of those 
admitted to hospital being 72 years.[9] The most common recorded comorbidities for 
admission to hospital across the UK are chronic cardiac disease [29%], diabetes 
[19%], chronic pulmonary disease excluding asthma [19%], and asthma [14%]. Just 
under half [47%] of patients had no documented comorbidity.[9]  
In other studies, those with obesity, cardiovascular disease [especially hypertension 
and heart failure], diabetes mellitus, respiratory disease, renal and liver disease were 
found to be the biggest factors in developing the more serious form of the disease 
and mortality. [10–12] Patients who are immunosuppressed or having had recent 
surgery are also recognised as being at risk, but this may be due to contact within 
the hospital setting.[11] In a New York analysis of patients with severe disease, 
hypertension, obesity and diabetes were found to be the most common factors for 
admission to hospital.[12] For all these chronic diseases there are a higher 
proportion of affected men, with a greater number affected at an earlier age. [13]  
Angiotensin converting enzyme 2 [ACE2] 
The angiotensin converting enzyme 2 [ACE2] is the main route the virus takes to get 
into cells,[14] and this is more highly expressed in males.[15] ACE2 is present in the 
lungs; the blood vessels, the renal tubular cells; the stomach and intestines; 
 
 
endothelial and smooth muscle cells in the human brain; and the Leydig and Sertoli 
cells in the seminiferous ducts in the testis. It is more highly expressed in smokers 
and in obese patients. 
The ACE2 receptor is part of the Renin Angiotensin Aldosterone System [RAAS], 
converting Angiotensin II into Angiotensin (1-7) via its binding to the Mas receptor. 
Angiotensin II is vasoconstrictive, pro-inflammatory and pro-coagulation - as well 
having a role in increasing blood pressure. Angiotensin (1-7), on the other hand, is 
vasodilatory, anti-inflammatory and has a role in glucose homeostasis, lipid 
metabolism, and energy balance and is both cardio-protective and neuro-protective 
and has a positive effect in reducing lung injury and kidney pathology. [16–18] The 
interaction between the virus and ACE2 leaves it depleted through receptor 
endocytosis and, therefore, leaves the damaging Angiotensin II unopposed, meaning 
that the body loses the positive effects of Angiotensin (1-7).[14] Losing the metabolic 
effect of Angiotensin (1-7) may also explain why both obese patients and those with 
diabetes are at greater risk. A link has also been made with the metabolic syndrome, 
which is more common in males, and the severity of the disease. [19]  
The ACE2 is produced by the X-chromosome, and as females have two X-
chromosomes they have twice the capacity to form the enzyme and tend to also 
create two types of the ACE2. As males only have one X-chromosome, they also 
have only one form of ACE2. This means that if the virus can unlock the single form 
of male ACE2 it has access to every cell in which the enzyme is present, while in 
women the virus has to unlock both of the two forms of ACE2 [one from each X-
chromosome] to have the same impact. The effect of this on males is two-fold: it 
means that the higher ACE2 levels in males may make it easier to get the infection; 
and once they are infected they may have less ACE2 and therefore Angiotensin (1-
7) available to help counter the damaging effects of Angiotensin II. For females there 
may be less virus entry into the cells, and also more remaining unaffected cells and 
Angiotensin (1-7) to tackle subsequent lung injury. 
Figure 1. Deaths attributed to COVID-19 infection in Great Britain, distributed 
by age and sex 19 June 2020.©statista.com 
The availability of the ACE2 is also affected by age, with highest levels found in the 
younger age patients, which would appear counterintuitive in relation to infection 
rates and severity of the disease in older age patients. However, as the young are 
less likely to have other risk factors [such as chronic diseases and comorbidities] 
they may be more able to use its protective function to fight the disease. In older age 
patients, a reduced ACE2 may mean the enzyme is more quickly exhausted, leading 
to the risk of more severe disease. 
The ACE2 is also highly expressed within the testis and the prostate,[15] with 
orchitis, infertility and testicular tumour identified in the earlier SARS-CoV 
outbreak.[6] The longer term impact of this ACE2 prevalence in male-specific organs 
should be assessed through the current outbreak.[22,23] It has also been postulated 




Endothelial dysfunction is an important risk factor for cardiovascular disease [CVD], 
and is of course frequently present in men with erectile dysfunction and Type 2 
diabetes. [20]  It appears the SARS-CoV-2 infection facilitates the induction of 
endotheliitis in multiple organs and the induction of apoptosis might play an 
important role in endothelial cell injury in these patients. From the practical viewpoint, 
using drugs that improve endothelial function, such as PDE5i’s ACE inhibitors and 
statins, could be very important in these patients, although many of the vulnerable 
patients will already be on these drugs because of pre-existing endothelial 
dysfunction and its known association with male sex and vascular risk factors. 
Coagulopathy 
In addition, the vascular immunopathology associated with COVID-19 presents as a 
diffuse pulmonary intravascular coagulopathy, which in its early stages is distinct 
from disseminated intravascular coagulation. Increased circulating D-dimer 
concentrations caused by pulmonary vascular bed thrombosis with resultant 
fibrinolysis and elevated cardiac enzyme concentrations in the face of normal 
fibrinogen and platelet levels are key early features of severe pulmonary 
intravascular coagulopathy related to COVID-19. Extensive immunothrombosis over 
a wide pulmonary vascular territory before the confirmation of early COVID-19 
viraemia possibly explains the adverse impact of male sex, hypertension, obesity, 
and diabetes on the prognosis of patients with COVID-19. The combination of 
immunomodulatory and anticoagulant strategies in patients with high D-dimer 
concentrations and evidence of myocardial stress requires urgent research. [21] 
Cytokine proteins 
The immune system is also supported by the cytokine proteins, which act as a 
communicator between cells. They are involved in the pro-inflammatory process, 
with some [CCL2, CCL3, CCL4 and CCL16] having a protective effect and being 
found more often in women. Although men to tend to have more of the interleukin 
cytokines [IL6ST, IL-7, IL-16 and IL-18] that provoke more of an inflammatory 
response and, with excess stimulation, can lead to the cytokine release syndrome [or 
cytokine storm] that can rapidly overtake the immune system of the body and result 
in a catastrophic shock. Men also tend to have more highly expressed TNFSF13b 
[BAFF], which is associated with an increased risk of inflammation and is associated 
with the progression of chronic obstructive pulmonary disease [COPD].[15]  
FURIN & TMPRSS2 
For the virus to get into the cells they also need two spike proteins [FURIN & 
TMRPSS2], with FURIN more highly expressed in the lungs of smokers [with men 
being more prevalent smokers] and TMPRSS2 is an androgen-responsive gene and 
more responsive to testosterone and dihydrotestosterone.[24] The modulation of 
transmembrane protease, serine 2 (TMPRSS2) expression by testosterone has been 
suggested to contribute to male predominance of COVID-19 infection. [25] This is 
because the androgen receptor activates the transcription of TMPRSS2 enhancing 
the transmissibility of COVID-19 infection [26] and because TMPRSS2 are 
expressed also at pulmonary level, the use of TMPRSS2 inhibitors, and 
 
 
antiandrogens are being investigated to modulate COVID-19 infections and treat 
COVID-19 pneumonia, and we await preliminary results. [27,28]  
Wider immunity factors 
Females also have higher expression of TLR7 and TLR8, both of which are 
important in immune responses and found [and remain active] on both of the X-
chromosome, whereas in men there is just a single copy. As such, females are more 
likely to activate a successful immune response and have been suggested to be 
more active with single strand viruses such as SARS-CoV-2.[29] 
A hormonal component is also at play, with oestrogen having an immuno-protective 
function by the regulation of myeloid cells and innate lymphocytes and in dampening 
the proinflammatory cytokines. It may also have a more direct effect on the metabolic 
function of the cell limiting viral replication. Oestrogen also promotes type 2 repair 
responses of alveolar macrophages and resolution of the immune response to the 
virus. In contrast, testosterone tend to have an immune-suppressive effect, by 
promoting the proinflammatory cytokines and suppressing inflammation.[6,30] Age 
may therefore have an effect on the viral infection, with oestrogen levels falling in 
women quickly in the perimenopause whereas testosterone levels remain stable in 
75% of men into old age, but this does leave a significant number of men 
testosterone and oestrogen deficient. [31] Risk factors for a low testosterone include 
type 2 diabetes, central obesity, erectile dysfunction, sleep apnoea, co-morbidity and 
others.[32] Female patients are able to achieve viral clearance significantly earlier 
than males, this may be because the testes was shown to be one of the highest sites 
of ACE2 expression in 3 independent RNA expression databases [Human Protein 
Atlas, FAMTOM5 and GETx]. ACE2 was also determined to be highly expressed in 
testicular cells at the protein levels. In contrast very little expression of ACE2 was 
seen in ovarian tissue.  High expression of ACE2 in testes raises the possibility that 
testicular viral reservoirs may play a role in viral persistence in males [33].  
Serum testosterone levels may be adversely affected by the testicular involvement 
and have a significant impact on recovery.[34]. Testosterone may also be helpful by 
downregulating inflammation. Testosterone deficiency [TD] is associated with 
increased pro-inflammatory cytokines and testosterone treatment reduces IL-1β, IL-
6, and TNF-α [35] A pro-inflammatory state and decline in testosterone has been 
demonstrated in aging men [36] and those with vascular disease. [37] In theory 
testosterone may have a role in the events leading to progression of COVID-19 
infection and the cytokine storm. Suppression of ACE2 expression by inflammatory 
cytokines accompanied by the decrease of androgen and oestrogen in some ageing 
men, may establish a negative correlation between ACE2 expression and COVID-19 
mortality. [26] Testosterone levels should be investigated in these men affected by 
COVID-19 because of the known adverse impact of testosterone deficiency on 
cardiovascular mortality and heart failure, and men with a low testosterone may be at 




We are not at the end of the pandemic, and there will be many more theories 
emerging as to the biological causes and consequences of the disease as our 
understanding develops. As the search for a vaccination continues apace there are 
many avenues being followed that may lead to a breakthrough, but this is proving to 
be a very tricky infection with many twists and turns in the experiences of patients. 
We fear we are just at the beginning… 
Declaration of interests: none declared. 
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Figure 1. Deaths attributed to COVID-19 infection in Great Britain, distributed by age 
and sex 19 June 2020.©statista.com 
Patient age group Male Female 
 
 
Under 1 year 2 0 
1 to 14 years  2  2  
15 to 44 years  325  206  
45 to 64 years  3104  1634  
65 to 74 years  4740  2542  
75 to 84 years  9446  6516  
85 years and over  9566  11286  
 
 
 
